Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Novartis brings on 8 business vets for Sandoz's new board, including 4 women
Fierce Pharma
Tue, 05/16/23 - 12:12 pm
Novartis
Sandoz
biosimilars
generics
women executives
The waxing and waning of the speedy approval
EP Vantage
Mon, 05/15/23 - 09:58 am
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Sandoz taps Evotec in long-term biosimilar development and manufacturing deal
Fierce Pharma
Wed, 05/10/23 - 10:00 am
Novartis
Sandoz
Evotec
biosimilars
A blockbuster year could be building
EP Vantage
Wed, 05/10/23 - 09:55 am
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations
BioSpace
Fri, 05/5/23 - 12:09 pm
Biogen
Novartis
Sanofi
earnings
R&D
Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold
Fierce Pharma
Thu, 05/4/23 - 09:00 pm
Novartis
Sandoz
generics
Adalvo
'More in the hopper': European Big Pharmas hint M&A could ramp up
Fierce Biotech
Mon, 05/1/23 - 10:15 am
Europe
M&A
GSK
Novartis
Roche
Novartis’s iptacopan meets primary endpoint in Phase III PNH trial
Clinical Trials Arena
Thu, 04/27/23 - 10:30 am
Novartis
clinical trials
PNH
iptacopan
Bristol Myers boosts cell therapy production with Novartis plant
BioPharma Dive
Wed, 04/26/23 - 05:40 pm
Bristol Myers Squibb
cell therapy
Novartis
drug manufacturing
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
BioSpace
Wed, 04/26/23 - 10:24 am
Novartis
earnings
solid tumors
hematology
immunology
Neuroscience
cardiovascular disease
Point looks to turn the tables on Novartis
EP Vantage
Wed, 04/26/23 - 09:55 am
Novartis
Point Biopharma
radiopharmaceuticals
Novartis, helped by cost cuts, raises full-year outlook
Reuters
Tue, 04/25/23 - 10:47 am
Novartis
earnings
Novartis strikes $425M deal with 3BP for FAP-targeting peptide technology
Medical Marketing and Media
Tue, 04/25/23 - 10:32 am
Novartis
3B Pharmaceuticals
FAP-targeting peptides
Novartis plant cleared to produce in-demand cancer drug
BioPharma Dive
Mon, 04/24/23 - 10:59 pm
Novartis
drug manufacturing
Pluvicto
New Jersey
cancer
radiopharmaceuticals
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Fri, 04/21/23 - 10:08 am
Daiichi Sankyo
Astellas
Novartis
quizartinib
FDA
blood cancer
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
Fri, 04/21/23 - 10:00 am
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
AACR 2023 – Hippo makes a splash
EP Vantage
Wed, 04/19/23 - 10:07 am
Vivace Therapeutics
VT3989
AACR
Novartis
Sanofi
Ikena Oncology
Double whammy: Supreme Court slaps down separate bids from Novartis, Sanofi
Fierce Pharma
Tue, 04/18/23 - 09:58 am
legal
Supreme Court
Novartis
Gilenya
Sanofi
Viatris
EpiPens
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Tue, 04/11/23 - 10:04 am
Novartis
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »